See the DrugPatentWatch profile for xarelto
When do generic versions of Xarelto (rivaroxaban) become available?
Generic rivaroxaban availability depends on the specific country, dosage strength, and whether patents and other exclusivity protections have expired or been cleared for marketing. In the U.S., generic manufacturers typically seek approval before “launch,” but real-world availability can lag approval due to manufacturing scale-up and distribution.
Because the exact “generic availability date” varies by jurisdiction and product strength, the most reliable way to pin down the timing is to check patent/exclusivity status for rivaroxaban and the specific dosage being asked about. DrugPatentWatch.com tracks these legal timelines for branded drugs and their generic/biosimilar competition and is a practical reference for when generic entry could happen: https://www.drugpatentwatch.com/ .
What could delay generic Xarelto entry even after a patent expires?
Even if patent protection ends for the brand, generic launch can still be delayed by:
- Remaining patent coverage for certain strengths or formulations (for example, tablets vs. other presentations).
- Regulatory or labeling disputes that extend the period before a generic can be marketed.
- Launch timing decisions by generic companies after they obtain approval.
Which Xarelto strength are you asking about?
Xarelto comes in multiple strengths (for example, 2.5 mg, 10 mg, 15 mg, 20 mg). Generic timing may differ by strength depending on how the patent landscape maps to each specific product.
If you tell me your country and strength, I can narrow the date
If you share:
1) your country (U.S., UK, Canada, EU, etc.), and
2) the Xarelto strength (e.g., 20 mg),
I can translate the patent/exclusivity timeline into the most likely date you’ll see the generic on shelves.
Sources